Back HIV Treatment

HIV Treatment

ASM Microbe 2016: Atripla 3 Times Weekly Maintains HIV Viral Suppression

People with undetectable viral load who switched from taking the Atripla single-tablet regimen (efavirenz/tenofovir/emtricitabine) every day to just every other weekday were able to maintain viral suppression for 6 months, and longer follow-up is planned, according to research presented last week at the ASM Microbe conference in Boston.

alt

Read more:

New California Grants Address Disparities in HIV Prevention and Care

An $9 million effort funded by the California HIV/AIDS Research Program (CHRP) will create new interventions tailored to reach heard-to-reach and heavily impacted groups living with or at risk for HIV, including homeless youth, HIV-positive young men of color, young people who use drugs or alcohol, the House Ball community, and women with barriers to care. The new initiative aims to increase HIV testing, treatment initiation, adherence to therapy, and retention in HIV care.

alt

Read more:

ASM Microbe 2016: PRO-140 Antibody Injections Maintain Viral Suppression Off ART

Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well-tolerated and maintained undetectable viral load for more than a year after stopping antiretroviral therapy (ART) in patients with viral suppression, according to a study presented at the ASM Microbe 2016 meeting this week in Boston.

alt

Read more:

Less Frequent CD4 and Viral Load Monitoring Safe for People Doing Well on ART

The frequency of routine monitoring for people treated with antiretrovirals who have viral suppression can be safely reduced from every 3 months to every 6 months, investigators from Europe and the U.S. reported in the June 1 edition of the Journal of Acquired Immune Deficiency Syndromes. However, people followed-up every 9 to 12 months were more likely to experience virological failure and also had lower CD4 cell increases compared to people monitored every 3 months.

alt

Read more:

Big Increase in Proportion of HIV+ People with Viral Suppression in US

The proportion of people living with HIV receiving care in the U.S. who accessed antiretroviral therapy (ART) and achieved viral suppression increased substantially between 2009 and 2013, according to research published in the May 20 online edition of AIDS.

alt

Read more: